Abstract
Alkaptonuria is a rare disorder of amino acid metabolism that causes premature large joint and spine arthropathy and cardiac valvular disease. It is characterised by elevated levels of homogentisic acid. Nitisinone (NTBC) is a benzoylcyclohexane-1,3-dione that reversibly inhibits the activity of the enzymatic step immediately prior to homogentisate dioxygenase, hence reducing the production of homogentisic acid. Thus it is thought that nitisinone might be a treatment for alkaptonuria. A side effect of NTBC therapy is elevation of plasma tyrosine levels in a manner analogous to tyrosinemia type 2, another related condition which causes a painful palmoplantar hyperkeratosis and eye pathology described as conjunctivitis and herpetic-like corneal ulceration. There are only two previous reports of NTBC causing eye symptoms in patients with alkaptonuria. Here we provide further evidence of this side effect of treatment and its resolution with cessation of NTBC. Repeat challenges with NTBC provoked symptoms, but introducing a low protein diet with low dose NTBC was successful in controlling plasma tyrosine levels and the patient remained free of symptoms when levels were below 600 μmol/L. Our patient was remarkable for the low dose of NTBC that precipitated symptoms (as little as 0.5 mg daily), and for the difficulty in proving its causation despite clinical suspicion.
Keywords
This is a preview of subscription content, log in via an institution.
References
Introne WJ, Perry MB, Troendle J et al (2011) A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 103(4):307–314
Phornphutkul C, Introne WJ, Perry MB et al (2002) Natural history of alkaptonuria. N Engl J Med 347(26):2111–2121
Ranganath LR, Milan AM, Hughes AT et al (2016) Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment. Ann Rheum Dis 75(2):362–367
Scott CR (2006) The genetic tyrosinemias. Am J Med Genet Part C Semin Med Genet 142C:121–126
Stewart RM, Briggs MC, Jarvis JC, Gallagher JA, Ranganath L (2014) Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report. JIMD Rep 17:1–6
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Daniela Karall
Appendices
Synopsis
NTBC used for the treatment of alkaptonuria may cause corneal crystalline keratopathy at low doses, and symptoms may be apparent prior to ophthalmic changes.
Declaration of Competing/Conflicts of Interest
The authors declare that they have no conflicts of interest.
Rights and permissions
Copyright information
© 2017 Society for the Study of Inborn Errors of Metabolism (SSIEM)
About this chapter
Cite this chapter
White, A., C. Tchan, M. (2017). Nitisinone-Induced Keratopathy in Alkaptonuria: A Challenging Diagnosis Despite Clinical Suspicion. In: Morava, E., Baumgartner, M., Patterson, M., Rahman, S., Zschocke, J., Peters, V. (eds) JIMD Reports, Volume 40. JIMD Reports, vol 40. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2017_56
Download citation
DOI: https://doi.org/10.1007/8904_2017_56
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57879-7
Online ISBN: 978-3-662-57880-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)